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Abstract
Bronchial asthma is characterised by high levels of immunoglobulin E (IgE) and overproduction of pro-inflammatory cytokines, inc-
luding interleukins IL-4, IL-13 and IL-5 needed for, amongst other things, the production of IgE and the differentiation, maturation, 
migration and survival of eosinophils. Eosinophils are one of the most important cells in allergic inflammation. Their presence in 
tissue is linked to the persistence of inflammatory infiltrate, tissue damage and remodelling. Although these cells are very sensitive 
to corticosteroids, some asthmatic patients do not respond to high doses of these drugs, even when administered systemically. 
Transbronchial biopsies and bronchoalveolar lavage performed in patients with steroid-resistant asthma have demonstrated higher 
levels of eosinophils and Th2-type cytokines (IL-4 and IL-5) compared to steroid-sensitive patients. Clinical studies have confir-
med that the very effective treatment in these cases is therapy with omalizumab — an anti-IgE monoclonal antibody. The paper 
discusses the efficacy of omalizumab in reducing eosinophil number in peripheral blood and in the airways of asthmatic patients 
based on basic, clinical, observational studies and case reports. The significance of omalizumab therapy in asthma control and 
mechanisms that regulate the effects of omalizumab on eosinophils are evaluated.
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Introduction
Asthma is an illness characterized by bron-
chial hyperreactivity, chronic inflammation and 
structural changes in the airways. Its pathogenesis 
involves a large number of cells and inflammatory 
mediators. Patients with bronchial asthma usu-
ally demonstrate high levels of immunoglobulin 
E (IgE) and overproduction of pro-inflammatory 
cytokines, including interleukins IL-4, IL-13 and 
IL-5, which are needed for, amongst other things, 
the production of IgE and the differentiation, ma-
turation, migration and survival of eosinophils. 
Mast cells, basophils, eosinophils, and lympho-
cytes play important role in the development of 
allergic inflammation. Apart from the inflamma-
tory cells, a significant role in the chronic phase 
is granted to structural cells such as epithelial 
cells, myocytes and fibroblasts. Among the many 
mediators of allergic reactions, the IgE molecule is 
regarded as playing a key role in this process. It is 
a leading element in the early stage of an allergic 
reaction as it initiates mast cell degranulation. It 
also participates as an immunoregulator in the 
late phase of the allergic reaction and mediates the 
development of eosinophilic inflammation. IgE is 
also believed to play a role in the remodelling that 
occurs in the airways [1]. Burrow et al. [2] report 
that a high level of IgE in plasma represents a risk 
factor for the development of bronchial asthma, 
and Kovac [3] and Carroll [4] also note that it 
correlates with the degree of severity. Hence im-
munoglobulin E represents a significant target for 
drugs used for treating asthma.
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Pharmacodynamic properties of omalizumab
The only drug currently used for the biologi-
cal treatment of bronchial asthma with anti-IgE 
activity is omalizumab — a humanised monoc-
lonal antibody created by recombining the DNA 
of Chinese hamster ovary cells, of which 95% 
of the sequence of omalizumab is in accordance 
with that of human immunoglobulin class G1. 
The medicine acts by selectively binding with 
free IgE molecules at the Ce3 domain. The formed 
IgE-drug complex prevents IgE binding to FceRI 
receptors, which have a high affinity for IgE, on 
mast cells and basophils. By doing so, it prevents 
the degranulation of these cells depending on the 
specific cross-linking of the allergen IgE bound 
to FceRI presented on the surface of these cells. 
Omalizumab does not bind the IgE molecules 
which are already complexed with the receptor, 
nor does it directly connect with IgE receptors, 
which avoids the harmful activation of mast cells 
and basophils [5].
The neutralisation of free IgE results in 
blocking the allergic reaction cascade by specific 
allergens at the level of mast cell and basophil 
activation, and as a consequence, preventing the 
development or reducing the allergic inflamma-
tion in the respiratory tract. Most importantly, 
omalizumab blocks the binding of IgE with FceRI 
localized on other cells, e.g. dendritic cells and 
this way affects the presentation of the allergen 
to Th2 lymphocytes, and on eosinophils, mo-
nocytes and airway epithelial cells, where the 
receptors probably perform a regulatory function. 
In addition, omalizumab blocks binding of IgE to 
specific receptors of low affinity (FceRII), found 
on B and T lymphocytes, eosinophils, macropha-
ges, dendritic cells and other cells involved in 
the development of chronic inflammation, thus 
trapping the allergen and presenting it to the T 
lymphocytes [6]. 
Apart from neutralising free IgE, long-term 
omalizumab therapy results in the reduction of 
IgE production by B lymphocytes. A theoretical 
model based on estimates from the results of the 
INNOVATE study calculated that 5-year omalizu-
mab treatment leads to the normalisation of the 
total production of IgE [7]. An important role in 
this phenomenon is played by Th2-lymphocytes 
and by IL-4 and IL-13 produced by Th2-lympho-
cytes [6]. Omalizumab was confirmed to reduce 
the amount of IL-4 [8] and IL-13 [9] positive cells 
and B lymphocytes in bronchial tissue [8].
Apart from direct effects of omalizumab on 
IgE and the regulation of IgE production, a signi-
ficant element of the pharmocological efficacy of 
omalizumab is its ability to indirectly modulate 
the course of allergic inflammation. For example, 
it decreases the expression of FceRI receptors on 
mast cells, basophils and dendritic cells. Bron-
chial bioptates from asthma patients, indepen-
dent of atopic status, and from atopic controls 
found a greater number of cells presenting FceRI 
on their surface (mainly mast cells and macropha-
ges) compared to healthy subjects without signs of 
atopy [10]. Particularly high expression was found 
in bronchial tissue taken from patients who had 
died during the course of a severe acute asthma 
attack [11]. It is known that FceRI expression on 
effector cells correlates with IgE concentration 
in serum and is dependent on the stimulation of 
these receptors through the IgE molecules bound 
to them. Most importantly, the binding of IgE to 
a receptor stabilises both IgE and the receptor [1, 
6, 12]. Omalizumab therapy quickly reduces the 
availability of free IgE to form complexes with 
the receptors (by 96% in three days) [13], and 
by doing so, inhibits the intracellular signalling 
from these receptors activating the synthesis and 
expression of these receptors on the cell surface. 
It has been shown that 16-week omalizumab 
therapy significantly reduces the number of IgE-
-positive and FceRI-positive cells in the bronchial 
submucosa [8]. As noted by Lin et al. [13], this 
inhibition of FceRI expression on basophils can be 
seen after seven days from omalizumab admini-
stration, and as MacGlashan et al. [14] demonstra-
ted, three months following the commencement 
of treatment, the inhibition effect is 96%. Chanez 
et al. [15] made a similar observation; the FceRI 
expression on basophils after 16 week-therapy 
with omalizumab decreased by 83%. A study 
conducted by Saini et al. [16] revealed that di-
scontinuation of omalizumab therapy results in 
a gradual increase of FceRI density on basophils 
simultaneously to the free IgE in serum, which 
confirms the active role of omalizumab in the 
inhibition of this receptor on basophils. 
A decrease in the FceRI expression on baso-
phils plays a functional role. It is associated with 
a lower histamine release, being a consequence of 
specific stimulation of basophils with an allergen 
but also a consequence of cellular lysis [17−19]. 
Besides, patients treated with omalizumab 
demonstrated a reduction of the number of pe-
ripheral basophils [20]. IgE is also believed to 
control homeostasis of human basophils. Oma-
lizumab similarly affects mast cells. However, 
this phenomenon occurs more slowly than for 
basophils and is associated with reduced skin 
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response to an allergen in skin prick tests [21]. 
Omalizumab therapy did not decrease the number 
of tryptase-positive cells in the skin. 
Also the FceRI expression on the surface of 
dendritic cells depends on the presence of IgE in 
the microenvironment. Prussin et al. observed that 
after 7 days following the commencement of omali-
zumab therapy the FceRI expression on precursors 
of dendritic cells, both of myeloid and lymphoid 
origin, is reduced [22]. The decrease in the FceRI 
expression on dendritic cells correlated with the de-
crease in its expression on basophils. Chanez et al. 
[15], who conducted similar studies on precursor 
of plasmacytoid dendritic cells, made similar 
conclusions. However, he did not find a correlation 
between decreased FceRI expression and clinical 
parameters [15]. Feuchtinger et al. [23] observed 
normalization of the number of dendritic cells in 
grass pollen season in patients with pollinosis al-
lergic to grass, who underwent specific immunothe-
rapy and were also administered omalizumab. The 
reduced number of dendritic cells and the FceRI 
expression on their surface potentially reduces the 
presentation of allergens to specific lymphocytes, 
thereby, decreasing their clonal activation. It mi-
ght reduce polarization of native Th to Th2 and 
production of Th2 cytokines contributing to the 
development of allergic inflammation. 
Eggel et al. [24] in their study revealed that 
omalizumab not only neutralizes free IgE and 
decreases expression but also might accelerate 
dissociation of IgE from FceRI on basophils. This 
observation was confirmed by Serrano-Candelas 
et al. [25] on mast cells. They also proved that 
this phenomenon is associated with IgE-depen-
dent decreased signalling from FceRI, connected 
with inhibition of proximal phosphorylation in 
the Syk-LAT-PLCg axis, as well as inhibition of 
degranulation and synthesis of leukotrienes. 
Neutralization of free IgE by omalizumab 
and its effect on the expression and function of 
FceRI are reflected in clinical phenomena, such 
as inhibition of early [26, 27] and late phase of 
allergic reaction [28, 29] and also a decrease in 
the severity of chronic allergic inflammation. 
Boulet et al. [26] conducted omalizumab 
therapy in patients with allergic asthma. They 
observed that on day 27 they had to administer 
a bigger than a double dose of allergen concentra-
tion in inhaled provocation in order to decrease 
FEV1 ( forced expiratory volume in 1 second) by 
15% (PC15 for the allergen) in the early phase of 
asthmatic reaction to the allergen. 
Zielen et al. [27] in their study reported that 
omalizumab therapy at 8 and 16 week significan-
tly inhibited post-allergenic bronchial contraction 
within 30 min. following the provocation and 
reduced the FeNO (fractional nitric oxide concen-
tration in exhaled breath) level measured 24 ho-
urs after bronchial provocation with an allergen, 
which implies inhibition of eosinophilic influx 
to the allergic reaction site in the late phase. This 
observation was confirmed by a study conducted 
by van Rensen et al. [29], who noted that a 12-
week omalizumab therapy inhibits early and late 
phases of asthmatic reactions after allergen chal-
lenge. This phenomenon was accompanied by 
a decrease in eosinophilic infiltration in bronchial 
bioptates, collected after 24 hours following the 
provocation. 
Due to constant or frequent exposure to 
a particular allergen, the late phase may turn into 
chronic inflammation (with remodelling) and lead 
to chronic dysfunction of the organ or system; and 
in the case of the bronchi — to the development 
of chronic bronchial asthma. 
Conversion of the late phase of an allergic 
reaction into a chronic inflammatory process still 
has not been clearly explained but mastocytes and 
eosinophils seem to play a key role in this process. 
Both populations play a role of effector cells. They 
coexist in tissues in the late phase of an allergic 
reaction and in the development phase of chronic 
inflammation and they probably maintain the in-
flammatory response. It was proved that both the 
populations can mutually affect their biological 
activity through released cytokines and a direct 
cell-to-cell (ligand-receptor) contact. This inte-
raction is strong and protects eosinophils against 
dexametazone-induced apoptosis [30]. Thus, the 
modulation of the number of both cellular popu-
lations, their functions and mutual interactions 
in the inflammatory infiltrate seems to be highly 
important in the control of chronic inflammation 
associated with asthma. Especially that asthmatic 
patients demonstrate an increased number of 
eosinophils in bronchial bioptates independent 
of atopia status in comparison to controls [31]. 
The number of mast cells in a study conducted 
by Macfarlane et al. did not significantly differ 
between asthmatic patients and healthy controls, 
whereas the number of basophils was significan-
tly higher in patients with atopic asthma but was 
not significantly different from the one observed 
in the inflammatory infiltrate in patients with 
non-atopic asthma [31].
It has been confirmed that omalizumab de-
creases the degree of chronic inflammation in 
the bronchi in asthmatic patients, probably by 
affecting eosinophils. Djukanovic et al. revealed 
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that 16-week omalizumab therapy decreased the 
percentage of eosinophils in induced sputum and 
tissue bioptates as well as decreased the number 
of CD3+, CD4+, CD8+ cells, B lymphocytes and 
IL-4-positive cells [8]8 . Van Rensen et al. [29] 
confirmed a considerable impact of omalizumab 
on tissue eosinophilia. In this study, 12-week 
omalizumab therapy contributed to a decrease 
in the number of eosinophils in induced sputum 
and a decrease in the eosinophilic infiltrate in 
bronchial tissue bioptates after allergen provoca-
tion. Besides, the researchers observed less cells 
presenting FceRI and CD4+ lymphocytes. 
Administration of omalizumab affects not 
only the number but also the function of eosino-
phils and lymphocytes. Noga et al. [9] observed 
in their study that 12-week omalizumab therapy 
increased eosinophilic apoptosis and decreased 
the number of T lymphocytes producing GM-CSF 
(granulocyte-macrophage colony-stimulating 
factor), IL-2 and IL-13 in peripheral blood. They 
did not observe differences with regards to the 
number of lymphocytes producing IL-5, IFN-g 
and TNF-a.
Inflammation-induced tissue damage is ac-
companied by reparative processes which lead to 
airway remodelling. Roth et al. [32] observed that 
IgE increases airway remodelling in asthma by 
activation of proliferation of smooth muscle cells 
as well as by increased extracellular deposition 
of pro-inflammatory collagen (Types: I, III, VII) 
and fibronectin. Such findings imply a potential 
role of omalizumab in airway remodelling. Ziet-
kowski et al. [33] noted that omalizumab therapy 
at 16 and 52 week following its commencement 
significantly reduces the level of endothelin-1 
(ET-1) in exhaled breath condensate which cor-
relates with a decrease in the FeNO level, eosi-
nophil number in peripheral blood and the ECP 
(eosinophil cationic protein) level in serum. ET-1 
plays an important role in the inflammation of 
the respiratory tract in asthmatic patients, par-
ticularly in the development of severe bronchial 
hyperreactivity and bronchial remodelling, by ac-
tivating proliferation of smooth muscle cells and 
by stimulating subepithelial fibrosis. Roth et al. 
[34] observed that administration of omalizumab 
inhibited proliferation of smooth muscle cells, 
stimulated in in vitro with the serum collected 
from patients with allergic asthma as well as 
decreased deposition of type 1 collagen and fi-
bronectin. Moreover, omalizumab affected the 
function of myocytes by inhibiting IgE-dependent 
synthesis and secretion of pro-inflammatory cy-
tokines (lL-4, IL-6, IL-8 and TNF-a) [35]. Huang 
at al. [36] noted inhibited production of TGF-b 
and pro-inflammatory cytokines (IL-4, IL-13 and 
TNF-a) by airway epithelial cells, stimulated by 
IL-1b and allergen. Hoshino et al. [37] studied a 
clinical effect of omalizumab with regards to the 
remodelling process by using high-resolution CT 
(computed tomography) of the thoracic cavity. A 
follow-up examination performed after 16 weeks 
demonstrated thinner bronchial wall in patients 
with severe asthma, treated with omalizumab. It 
correlated with improved values of spirometry 
(FEV1) and a decreased number of eosinophils in 
induced sputum.
The clinical efficacy of omalizumab in the 
control of chronic bronchial asthma has been 
confirmed in many clinical studies and meta-a-
nalyses [5]. In 2002, this drug was registered to 
be administered in therapies of uncontrolled 
moderate and severe asthma in Australia; in 2003 
in the United States of America and in 2005 in 
the European Union as an add-on therapy to high 
doses of inhaled corticosteroids in combination 
with long acting b2-agonists (LABA) in patients 
with frequent exacerbations and in 2014 in the 
treatment of spontaneous persistent urticaria.
The investigators of a 28-week randomized, 
double-blind and placebo-controlled study, called 
INNOVATE [38], evaluated the efficacy of omali-
zumab in a group of patients with severe asthma, 
in whom the disease control was not achieved 
after administration of high doses of inhaled 
corticosteroids in combination with LABA. Part 
of the studied patients (60%) took the third drug 
controlling asthma. Of this percentage, 22% took 
oral corticosteroids. Adding omalizumab to the 
optimized therapy decreased the frequency of 
significantly clinical exacerbations by 26%, the 
frequency of severe exacerbations by 50% and the 
frequency of emergency medical interventions by 
44%. Besides, omalizumab improved the quality 
of life, morning PEF (peak expiratory flow) value 
and decreased asthma symptoms. On the base of 
the INNOVATE study the researchers concluded 
that the omalizumab therapy should be carried 
out in 2.7 patients (NNT, number needed to treat) 
in order to prevent one clinically significant exa-
cerbation, in 2.0 patients to prevent one severe 
exacerbation. So as to prevent a single medical 
intervention, the omalizumab therapy should be 
carried out in 2.8 patients [39]. 
Meta-analysis of 25 clinical studies [40], 
conducted in 2014 by Cochrane experts, based 
on studies where omalizumab was administered 
to patients with moderate and severe bronchial 
asthma, demonstrated that the drug was effective 
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in reduction of exacerbations and hospitalisations 
due to exacerbations. It also implies that patients 
taking omalizumab can reduce doses of the drug 
or even discontinue the therapy with inhaled 
corticosteroids more frequently in comparison 
to the placebo group, whereas patients who were 
administered long-term therapies with oral cor-
ticosteroids, demonstrate better asthma control 
when they received omalizumab; however, the 
steroid-sparing omalizumab effect requires fur-
ther prospective studies. 
A pooled analysis of 6 studies, conducted 
by Chipps et al. [41], evaluating the effect of 
omalizumab therapy on the quality of life of pa-
tients with severe uncontrolled asthma, revealed 
a significant improvement in limiting activities 
due to the disease, emotions, symptoms and 
exposure to environmental factors in the group of 
patients treated with omalizumab in comparison 
to patients who were administered optimized 
pharmacological treatment.
The authors’ own experience confirms con-
siderable benefits from omalizumab therapy in 
patients with severe allergic asthma, including 
better asthma control and better quality of life, 
reduced frequency of exacerbations and reduced 
degree of exacerbations as well as decreased oral 
corticosteroid demands [42].
Currently, omalizumab is recommended 
by GINA (global initiative for asthma) experts 
in patients with moderate and severe bronchial 
asthma at the 5th stage of the therapy, before oral 
corticosteroids have been permanently admini-
stered [43].
The role of eosinophils in bronchial asthma
Eosinophils are key inflammatory infiltration 
cells of the late-phase allergic reactions and chro-
nic inflammatory process in bronchial asthma. 
Their presence in the tissues is associated with 
persistence of the inflammatory infiltrate, tissue 
injury and remodelling [1]. Eosinophils are for-
med in bone marrow from eosinophil/basophil 
colony forming units (Eo/B-CFU). IL-3, IL-5 and 
GM-CSF play a vital role in the differentiation, 
maturation and migration of eosinophils out of 
the bone marrow into the circulation, with IL-5 
being the most important and most specific for 
eosinophils at this stage of their development. 
These hematopoietic cytokines are produced 
at the site of allergic reaction and endocrinally 
exert impact on the bone marrow. It has been 
shown, however, that activated T cells can also 
migrate to the bone marrow and locally secrete 
IL-5. Eosinophils migrate with blood to the sites 
of the ongoing inflammation as they are attracted 
by chemotactic factors: eotaxins, MCP5 (mono-
cyte chemotactic protein 5), MIP1a (macrophage 
inflammatory protein-1a) and RANTES (regulated 
on activation , normal T-cell expressed and secre-
ted). IL-4, IL-13, IL-1 and TNF facilitate eosino-
phil migration from blood to the inflammatory 
tissue and increase the expression of adhesion 
molecules on endothelial cells. 
Eosinophils, at the site of inflammation, are 
activated by cytokines, leukotrienes and comple-
ment components and release pro-inflammatory 
mediators responsible for the influx and activa-
tion of other inflammatory cells and processes 
of tissue damage and regeneration. They include 
enzymes (elastase, collagenase), cationic pro-
teins (major basic protein — MBP), eosinophil 
peroxidase (EPO), ECP; free radicals and reactive 
oxygen species, platelet-activating factor (PAF), 
leukotrienes and numerous cytokines (such as 
IL-3 and IL-5, GM-CSF, SCF, IL-4 and IL-13, IFN-g, 
eotaxin, RANTES and TGF-b) [1].
The presence of eosinophils in the cell infil-
trate in the bronchi is a characteristic feature of 
the inflammation in asthma patients. The results 
of studies showing a correlation between the 
concentration of ECP and the severity of the late-
phase asthmatic reaction are the evidence for the 
active role of eosinophils in the development of 
the late-phase asthmatic reaction [44].
It was further indicated that the number of 
eosinophils in sputum (reflecting the severity of 
inflammation in the bronchial tissue) closely cor-
relates with asthma severity as well as the risk and 
severity of exacerbations [45]. In patients with re-
current asthma exacerbations, anti-inflammatory 
treatment based on the result of induced sputum 
cytology with the assessment of the presence of 
eosinophils was more effective than that carried 
out on the basis of symptoms and lung function 
[46]. Eosinophilic airway inflammation in asthma 
is usually accompanied by mild eosinophilia in 
peripheral blood, although eosinophilia in the 
tissues, nasal secretions, sputum and broncho-
alveolar lavage (BAL) is usually significantly 
higher [47].
Eosinophils are very sensitive to corticoste-
roids. Corticosteroids are considered to be the 
strongest anti-inflammatory drugs in asthma and 
in an inhaled form are recommended in all types 
of chronic asthma [44]. However, there is a group 
of asthmatic patients who do not respond to even 
high doses of these drugs even when are admi-
nistered systemically. Transbronchial biopsies 
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and BAL which are performed in patients with 
steroid-resistant asthma show an increase in eosi-
nophil and Th2-type cytokine (IL-4 and IL-5) level 
compared to steroid-sensitive patients [48, 49]. 
The following mechanisms for this phenomenon 
are postulated [50, 51]: the decrease in the affinity 
of corticosteroid receptors to corticosteroids (CS) 
as a result of an increased type b CS receptor 
expression in steroid-resistant patients, reduced 
CS receptor binding to sensitive nuclear elements 
or no inhibition of c-Jun N-terminal phospho-
rylation, or genetic predisposition such as the 
polymorphism of the gene encoding the cortico-
steroid receptor, h-GCR/NR3C1. These patients 
despite the use of CS exhibit local and systemic 
eosinophilia. Further increase in the CS dose may 
not provide a measurable clinical effect, but is 
associated with the risk of serious side effects. 
Part of the events leading to the development of 
steroid resistance seems to be reversible and is 
a potential target for pharmacological intervention. 
The impact of omalizumab on eosinophilia in 
asthma patients in clinical and observational 
trials as well as in case reports
In the study by Noga et al. [18], omalizumab 
therapy significantly reduced the percentage of 
peripheral eosinophils at the 16th and 52nd week 
from its commencement. While Tataku et al. [52] 
observed a significant reduction in the number of 
eosinophils in induced sputum and FeNO levels 
after 16 weeks of therapy with omalizumab in pa-
tients with severe uncontrolled bronchial asthma.
In Massanari’s pooled analysis of five clini-
cal trials [53] on the efficacy of omalizumab in 
patients with persistent moderate/severe allergic 
asthma, the post-treatment number of peripheral 
eosinophils compared to baseline was reduced 
only in the group of patients receiving omalizu-
mab, with a greater reduction in eosinophil count 
observed in those in whom the serum free IgE 
levels were lower than 50 ng/ml. The researchers 
also found a correlation between the omalizu-
mab-induced decrease in peripheral eosinophils 
and various clinical parameters, including the 
occurrence of severe exacerbations, FEV1 value, 
a response to omalizumab treatment assessed by 
physicians on GETE (the Global Evaluation of Tre-
atment Effectiveness) scale (correlation between 
clinical improvement and reduction in the num-
ber of eosinophils and between no improvement 
and increase in the number of eosinophils).
In the EXTRA study conducted by Hanania et al. 
[54] a clinically significant reduction (by 56%) 
in the frequency of severe asthma exacerbations 
following the treatment with omalizumab was 
achieved only in the high peripheral eosinophilia 
group (≥ 260 EO/µl) as compared to the placebo 
group. A similar effect was observed for FeNO 
and serum periostin levels, which are considered 
biomarkers for eosinophilic airway inflammation. 
Zietkowski et al. [55] also showed a significant 
decrease in the peripheral eosinophil count, 
ECP level and FeNO level, which correlated with 
a decrease in eotaxin levels in the exhaled breath 
condensate in patients with asthma, who were 
treated with omalizumab. Whereas Skiepko et al. 
[56] observed that a decrease in the peripheral 
eosinophil number by 50% under the influence 
of the treatment with omalizumab compared to 
baseline was associated with a lower frequency 
of severe exacerbations than in the group with 
a smaller reduction in the number of eosinophils. 
The authors of that study indicated that monito-
ring peripheral eosinophil levels in the course of 
omalizumab therapy could be a useful marker of 
response to omalizumab and a predictor of future 
exacerbations.
Our experience shows that omalizumab is 
highly effective in patients with allergic asthma 
and peripheral and tissue hypereosinophilia. The 
authors described a case of a patient with uncon-
trolled severe allergic asthma sensitive to house 
dust mites and Alternaria alternata. with peri-
pheral (1700 Eo/µl) and tissue (in BAL Eo 56%) 
hypereosinophilia, in whom the treatment with 
high doses of inhaled and systemic corticosteroids 
did not result in normalization of the eosinophil 
number [57]. Inclusion of omalizumab into the 
treatment caused a significant improvement in 
the disease control, with a four-fold reduction in 
the demand for systemic corticosteroids as well 
as normalization of peripheral eosinophil count. 
We observed normalization of eosinophil level 
during treatment with omalizumab despite the 
reduction in the daily dose of systemic cortico-
steroids in another patient suffering from severe 
uncontrolled allergic asthma with concomitant 
chronic urticaria and life-threatening angioede-
ma as well as hypersensitivity to non-steroidal 
anti-inflammatory drugs and hypereosinophilia 
in peripheral blood [58].
Pelaia et al. [59] showed similar results. They 
applied omalizumab in five asthma patients with 
persistent peripheral eosinophilia (mean Eo % 
of WBC ± SD: 15.9 ± 8.0%; Eo 1588.0 ± 956.9 
cells/µl) despite long-term treatment with inhaled 
and systemic corticosteroids. After 16 weeks of 
treatment with omalizumab, the number of peri-
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pheral eosinophils was almost normalized (mean 
± SD: 6.3 ± 2.3% of WBC; absolute numbers: 
462.0 ± 262.3/µl) at lowered daily doses of oral 
corticosteroids. The number of exacerbations 
also decreased.
These studies and observations show that 
eosinophilia in the peripheral blood, sputum, 
BAL and bronchial bioptates may be an important 
marker for a clinical response to omalizumab. 
Complete peripheral blood counts with granulo-
cyte differentiation seem to be useful in monito-
ring the treatment with omalizumab.
Efficacy of omalizumab in syndromes  
with eosinophilia
Omalizumab efficacy in eosinophilic inflam-
mation is confirmed by case reports describing 
syndromes with eosinophilia in which the IgE-
mediated activation is not a key pathomechanism 
of the disease nor is involved in the pathomecha-
nism at all. Thus, the beneficial effect of omalizu-
mab action was observed in bronchopulmonary 
aspergillosis [60, 61], Churg-Strauss syndrome 
[62, 63], eosinophilic pneumonia [64], Kimura 
disease [65], eosinophilic otitis media [66], and 
eosinophilic gastrointestinal syndromes [67].
The authors’ experience shows that omalizu-
mab is efficacious in asthma with hypersensitivity 
to nonsteroidal anti-inflammatory drugs (NSAIDs) 
accompanied usually by high peripheral and 
tissue eosinophilia [68]. Asthma in these patients 
is often severe, even if they avoid using NSAIDs. 
It is known that the mechanism for NSAID-indu-
ced hypersensitivity is IgE–independent and is 
associated with inhibition of cyclooxygenase-1 
(COX-1) and overproduction of leukotrienes. Un-
doubtedly, eosinophils play a significant role in 
the development of hypersensitivity and in the 
clinical picture, being a rich source of cysteinyl 
leukotrienes [69]. Case reports of patients in whom 
the tolerance to higher doses of NSAIDs was obta-
ined after the treatment with omalizumab confirm 
the efficacy of omalizumab in aspirin-induced 
asthma [70−73].
Mechanisms of omalizumab effect  
on eosinophils 
Anti-eosinophilic action of omalizumab is 
manifested by the decrease in the number of eosi-
nophils in peripheral blood and tissues and by 
the impact on eosinophil survival and functions 
(Fig. 1). Studies on the mechanism of this action 
are currently limited to allergic diseases.
It is known that omalizumab does not act 
directly on eosinophils, but modulates the 
environment in which they differentiate, migrate, 
become activated and undergo apoptosis.
High- and low-affinity IgE receptors are found 
on the surface of eosinophils, thus potentially 
the reduction in free IgE might be important for 
functioning and survival of eosinophils in blood 
and tissues. Immunohistochemical and immuno-
cytochemical studies carried out in patients with 
allergic diseases showed that the local allergen 
challenge induces the expression of FceRI on 
eosinophils infiltrating the respiratory system [74] 
and skin [75, 76]. Moreover, the presence of FceRI 
was also confirmed on peripheral eosinophils in 
patients with various forms of allergic diseases 
[77]. In contrast to the presented studies, Semi-
nario et al. [78] were not able to detect FceRI on 
the surface of eosinophils while observing a large 
amount of FceRIa intracellularly, and showed 
its release to the medium in a form of a soluble 
receptor. Kita et al. [79] confirmed a low surface 
expression of FceRI on eosinophils by using the 
highly sensitive biotin-streptavidin method. In 
the light of these results, the synthesis of this 
receptor protein and its expression on the surface 
of eosinophils seem to be regulated by different 
mechanisms. Hence, the differences between the 
results of immunohistochemical examinations 
evaluating the presence of the protein regardless 
of the cellular location and the assessment of this 
receptor expression on the surface of eosinophils 
were found by using the biotin–streptavidin 
technique. Functional significance of the FceRI 
expression on eosinophils poses another problem. 
In parasitic diseases, the FceRI activation leads to 
degranulation of eosinophils and is involved in 
the cytotoxic response mediated by eosinophils 
[80]. The role of FceRI on eosinophils in allergic 
diseases has not been entirely elucidated.
Tomassini et al. [81] conducted an expe-
riment in which they stimulated eosinophils, 
isolated from allergic patients, with allergens 
and anti-IgE, anti-IgA and anti-IgG antibodies. 
Stimulation with specific allergens, to which 
patients were sensitive, and with anti-IgE anti-
bodies induced the release of EPO but not ECP 
from eosinophils, anti-IgG stimulation activated 
eosinophils to release ECP but not EPO, while 
anti-IgA stimulation released both ECP and 
EPO from eosinophils. The authors concluded 
that eosinophils selectively release mediators as 
a result of stimulation of membrane receptors for 
immunoglobulins according to their type. Kayaba 
et al. [82] demonstrated that the IgE-mediated ac-
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Figure 1. The mechanisms of omalizumab action on eosinophilic inflammation
tivation of eosinophils leads to secretion of IL-10, 
which may indicate their immunoregulatory 
role in inflammation. In contrast, Kita et al. [79] 
did not observe any significant biological effect 
(degranulation or production of oxygen radicals 
or release of leukotriene C4) after the FceRI sti-
mulation on eosinophils.
Differences in the response of basophils and 
eosinophils to stimulation by FceRI may arise 
from the surface presentation of this receptor. The 
number of FceRI on eosinophils, as compared to 
basophils, is several-fold lower (representing ap-
proximately 0.5%), hence this way of regulation, 
if of any significance, is rather secondary.
Moreover, research concerning the function 
of FceRII on eosinophils is ambiguous. Capron et 
al. [83] observed that the use of anti-CD23 mAb 
can inhibit IgE-dependent cytotoxicity of eosino-
phils. Lantero et al. [84] reported that the IgE-me-
diated stimulation of eosinophils from atopic and 
non-atopic patients by FceRII leads to functional 
changes characterized by the increased migration 
of eosinophils associated with the increased LFA-1 
(lymphocyte function-associated antigen 1) and 
Mac-1 (macrophage-1 antigen) expression. Arock 
et al. [85] demonstrated that the activation of Fce-
RII causes the release of TNF-a by eosinophils, 
in which the participation of IL-4 is significant. 
The expression of this receptor depends on the 
stimulation of IL-3 and GM-CSF [86].
To date, no studies on the effects of omali-
zumab on the expression and function of these 
receptors on eosinophils have been performed, 
however their low expression and the lack of 
direct relationship between the expression and 
total IgE level suggest a different mechanism of 
drug action in eosinophilic inflammation.
In allergic diseases, three major eosinophil 
activation pathways, the Th-2-dependent, Th-
1-dependent and associated with the mechanisms 
of innate immunity, are postulated. The Th-2-de-
pendent pathway, mediated primarily by IL-5, is 
most important in allergic diseases [87].
Hubner et al. [88] observed that the pa-
tients with a clinical response to omalizumab 
had higher pre-treatment serum IL-5 levels and 
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a pronounced decrease in serum IL-5 following 
omalizumab compared to non-responders. Taka-
ku et al. [52] found that the 16-week treatment 
with omalizumab decreases the production of 
IL-5 through peripheral mononuclear cells. In 
contrast, Noga et al. [9] failed to demonstrate the 
reduction in the number of lymphocytes produ-
cing IL-5 in peripheral blood due to the treatment 
with omalizumab, although Djukanovic et al. [8] 
reported that the 16-week treatment with omali-
zumab resulted in the reduction in the number of 
CD3+, CD4+, CD8+ cells in induced sputum and 
tissue bioptates. Probably, local inhibition of the 
IL-5 production via Th-2 in the inflamed tissues 
is of decisive importance. Besides lymphocytes, 
eosinophils, mast cells and basophils are a rich 
source of IL-5 [89].
It is known that omalizumab decreases eosi-
nophilia in peripheral blood as well as in the 
tissues. Chemotactic factors are responsible for 
the influx of eosinophils to the site of inflam-
matory reaction. The study by Zietkowki et al. 
revealed that omalizumab therapy reduces the 
level of eotaxin [55] and RANTES [90] — strong 
chemoattractants for eosinophils — in the air 
exhausted by patients with allergic asthma.
Adhesive molecules displayed on the endo-
thelial cells and eosinophils, including VCAM-1 
(vascular cell adhesion molecule 1) and VLA-4 
(very late antigen-4), are involved in the migration 
of eosinophils from blood vessels into the tissues. 
Their expression is increased by IL-4 and IL-13 
[91]. Omalizumab has been found to affect the 
production of these cytokines [8, 9, 37], thus it can 
potentially also influence eosinophil diapedesis.
An important element of the persistence of 
eosinophilic inflammation is impaired eosinophil 
apoptosis in allergic diseases. Two mechanisms, 
active and passive, of apoptosis activation in eosi-
nophils have been known. An active mechanism 
depends on the activation of the Fas receptor, 
which is universal for the leukocyte population 
or is associated with the activation of the CD69 
receptor. A passive pathway is associated with a 
decrease in the levels of growth factors for eosi-
nophils, such as IL-3, IL-5 and GM-CSF, in the 
eosinophil microenvironment [92].
Noga et al. [9] confirmed that omalizumab 
therapy induces apoptosis in eosinophils, whose 
marker is annexin V. No changes in 7-amino-acti-
nomycin level (a marker of necrosis) or eosinophil 
activation CD69 or Fas receptor (CD95) were de-
tected. An increase in eosinophil apoptosis during 
treatment with omalizumab should therefore be 
associated with the passive mechanism, which 
largely depends on the reduction in the level of 
IL-5 [89] and possibly GM-CSF [9].
In addition to the mentioned above me-
chanisms, apoptosis is affected by the presence 
of nitric oxide (NO) in the site of eosinophilic 
inflammation. NO inhibits apoptosis dependent 
on the activation of the Fas receptor [93]. Incre-
ased levels of NO are observed in asthma, while 
omalizumab therapy significantly reduces the 
NO concentration in the exhaled air [28, 34, 53, 
55, 56], which may be important for regression of 
eosinophilic inflammation in the airways.
Conclusions
Clinical efficacy of omalizumab has been 
confirmed in numerous clinical trials. Its pharma-
cological mechanism of action is more complex 
than it has been originally thought. In addition to 
inhibition of the early and late allergic reaction 
associated with the activation of mast cells and 
basophils via FceRI, it also affects chronic aller-
gic inflammation, mainly through the reduction 
in eosinophilic infiltration. Omalizumab impact 
on eosinophils is indirect through inhibiting 
the production of proinflammatory cytokines by 
mast cells, basophils and Th-2 cells and concerns 
different stages of the life of these cells from the 
differentiation in the bone marrow, migration to 
the tissues, and activation, to apoptosis. Clinical 
efficacy of omalizumab in asthma has been fo-
und to correlate with the level of eosinophils in 
peripheral blood and the bronchi and with their 
activity, so this mechanism of action seems to 
be as important as blocking the IgE-dependent 
pathway and may be responsible for the efficacy 
of this drug in non-allergic asthma [94, 95]. The 
clinical anti-eosinophilic efficacy of omalizumab 
has been confirmed by case reports on efficacy of 
therapy with this drug in eosinophilic syndromes 
not associated with allergic inflammation.
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